Aquinox Pharmaceutical shared its Phase 3 Leadership 301 clinical trial with oral rosiptor (AQX-1125) for the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS) failed to meet its primary endpoint resulted in a major share price decrease.
The post Aquinox Faces Major Share Price Drop With Topline Clinical Results appeared first on Investing News Network.
Original Article: Aquinox Faces Major Share Price Drop With Topline Clinical Results